Does Blinatumomab Interact with Cyclosporine?
CDI records a moderate classification for Blinatumomab and Cyclosporine. The stored summary is: BLINATUMOMAB causes transient cytokine release that may suppress CYP450 enzymes, potentially increasing cyclosporine concentrations. Monitor drug levels during first 9 days of first cycle and first 2 days of second cycle. The mechanism involves cyp450 enzyme suppression due to cytokine release. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Cyclosporine Class
- Calcineurin Inhibitor Immunosuppressant
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP450 enzyme suppression due to cytokine release
What To Tell Your Doctor or Pharmacist
If you are taking Blinatumomab and your doctor is considering prescribing Cyclosporine (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider